Abstract
Summary
The repeated oral administration of TACE to human subjects results in storage of considerable amounts of estrogenic material in the body fat. This material remains in the fat for prolonged periods following cessation of TACE therapy. Results of studies in a limited number of cases suggest that both duration of therapy and the size of the doses are contributing factors governing the level of estrogenic material in the fat.
Get full access to this article
View all access options for this article.
